Arvinas, Inc., a clinical-stage biotechnology company specializing in targeted protein degradation, has announced its participation in two major investor conferences this November. From New Haven to London, Arvinas aims to present its progress to analysts, investors, and the broader scientific community via a live audio webcast.

In a newly revealed study, scientists have captured the first high-resolution 3D structure of a critical malaria parasite protein. Researchers believe this discovery may pave the way for significantly improved anti-malarial treatments.

LB Pharmaceuticals is seeking $228 million through an IPO on the Nasdaq, hoping to become the first biotech to go public since February. The New York-based firm plans to build on medicines that have long been used to treat schizophrenia, aiming to put a modern spin on an established therapy.